Liletta LNG IUS

Product Overview

Alternative Name: Levosert (U.K.), Erlacela (Portugal), Donasert (Romania)

Development Status: SRA/WHO PQ Approved

Target: Female

Mode: Hormonal

Delivery Type: Intrauterine

Duration Type: Long-acting

Description: LILETTA is the brand name for the levonorgestrel-releasing intrauterine system (LNG-IUS) marketed by Medicines360 and Actavis in the U.S., where it is approved for 3 years of use for contraception.

Updated date: May 30, 2018

Vertical Tabs


Project Phase: Post-development

Project Stage: Marketed

Status Details:
  • Medicines360 received U.S. FDA approval for Liletta in February 2015 and the product launched in the U.S. in April 2015.
  • As of April 2015, the product is also approved in more than a dozen countries in Europe, including in the U.K. for 3 years of contraception and treatment of menorrhagia.
  • In 2014, a public-private partnership was launched between Medicines360, FHI 360 and Marie Stopes International (MSI) to support the development of an introduction strategy for the product in Kenya.

Download Product Report